Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VENTURA-5: Aticaprant Plus Antidepressant for Relapse Prevention in MDD With Anhedonia
NCT06635135Phase 3Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2024
- Primary completion
- Apr 2025
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Aticaprant with Placebo (2 arms). Primary endpoint: Time From Randomization Into Double Blind (DB) Treatment Maintenance Phase to the First Documentation of Relapse. Started Sep 2024; status: terminated.
02
Drugs
aticaprant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06635135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06635135.